Thomas Lehmann
6PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Aug 17, 2023
Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.Judith Everts-Graber, Harald Bonel, Daniel Lehmann
|Jul 26, 2023
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.Judith Everts-Graber, Harald Bonel, Daniel Lehmann
|Oct 17, 2022
Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy-A Registry-Based Cohort Study.Judith Everts-Graber, Harald Bonel, Daniel Lehmann
|Aug 04, 2022
Reply to Potential Issues With the Use of Teriparatide After Denosumab-Related Osteonecrosis of the Jaw.Judith Everts-Graber, John-Patrik Burkhard, Benoît Schaller
|Nov 17, 2021
Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.Judith Everts-Graber, Daniel Lehmann, John-Patrik Burkard
|Jan 29, 2020
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.Judith Everts-Graber, Stephan Reichenbach, Hans Rudolf Ziswiler
Pageof 1
